Bristol Vanlev Limited Distribution Necessary For Approval, Cmte. Says
Executive Summary
Bristol's Vanlev angioedema risk management program should require a limited distribution system to support approval of the antihypertensive agent, FDA's Cardiovascular & Renal Drugs Advisory Committee recommended July 19
You may also be interested in...
Bristol Vanlev Trial In Refractory Patients Could Support Approval, Cmte. Says
Results from a trial of Bristol-Myers Squibb's Vanlev in highly refractory hypertension patients showing a benefit over current therapy could outweigh safety concerns with the drug and lead to approval, FDA's Cardiovascular & Renal Drugs Advisory Committee concluded at its July 19 meeting
GSK Lotronex Plan Follows Accutane Model; Relaunch “Months” Away
GlaxoSmithKline's Lotronex risk management program will follow the Accutane model
Actelion Will Launch Tracleer Through Closed Distribution System
Actelion's launch of the pulmonary hypertension drug Tracleer will include converting 200 patients in an ongoing, open-label trial to its closed commercial distribution system, the company told analysts Nov. 21